Patients
infection, major cancer
PANCREATIC CARCINOMA, CEREBRAL METASTASES, METASTATIC PANCREATIC CANCER, INFECTION, CARDIAC DISEASE, ONCOLOGY, PERIPHERAL NEUROPATHY, CHRONIC DIARRHEA
Patients were eligible if they were 18 years of age or older and had histologically or cytologically confirmed, measurable by RECIST version 1.1, previously untreated metastatic PDAC. Other inclusion criteria were an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 and adequate bone marrow (granulocyte count >/= 1500 per cubic millimeter; and platelet count >/= 100 000 per cubic millimeter), liver (bilirubin </= 1.5 times the upper limit of the normal range), and renal (creatinine >/= 1.5 times the upper limit of the normal range OR creatinine clearance >/= 60 mL/minutes/1.73 mPrior systemic treatments were permitted if they received (1) adjuvant treatment after surgical resection with single-agent gemcitabine, gemcitabine/capecitabine, or 5-fluorouracil/leucovorin if completed >12 months before enrollment; (2) adjuvant radiation with or without chemotherapy sensitization with 5-fluorouracil, capecitabine, or gemcitabine if completed > 12 months before enrollment; (3) neoadjuvant treatment prior to surgical resection with single-agent gemcitabine or 5-fluorouracil/leucovorin/oxaliplatin/irinotecan if completed >12 months before enrollment.Exclusion criteria were an endocrine or acinar cell pancreatic carcinoma, previous chemotherapy for locally advanced or metastatic pancreatic cancer, radiotherapy for measurable lesions, concurrent use of any other anti-cancer therapy, cerebral metastases, history of another major cancer, active infection, chronic diarrhea, pre-existing peripheral neuropathy (CTCAE grade 2 or higher), clinically significant history of cardiac disease, and pregnancy or breast-feeding.